Improvement of cutaneous anaplastic large cell lymphoma by brentuximab vedotin monotherapy

Takashi Onaka
Kokura-Kita ku Asano 3-2-1 Kitakyushu Fukuoka 802-8555, Japan
T: 81-093-511-2000
takashionaka3@gmail.com

Tomoya Kitagawa
Fukuoka, Japan

Chika Kawakami
Dermatology, Fukuoka, Japan

Akihito Yonezawa
Fukuoka, Japan
Brentuximab vedotin (BV) is an antibody-drug conjugate composed of a CD30-directed monoclonal antibody and monomethyl auristatin E (MMAE)\(^{1}\). BV monotherapy was showed good response rates for refractory and relapsed anaplastic large cell lymphoma (ALCL), but only a few case reports are available for cutaneous localized ALCL (cALCL). We herein reported the treatment with BV for relapsed cALCL with an excellent response. An 82-year-old female who relapsed cALCL had generalized erythema accompanied by desquamation and could not extend her fingers enough (Figure 1) without lymph node lesions. Due to the previous treatment with radiation, steroid ointment, and systemic chemotherapy, we chose BV monotherapy dosing at 1.8 mg/kg every 21 days for her. After the third infusion, her generalized erythema and her finger movement had been improved (Figure 2). She did not have any severe adverse effects and the infusion reaction except for hematologic toxicity (leukocytopenia). She has finished 6 courses BV infusion and maintained remission of skin lesions. There are several reports which showed effectiveness of BV treatment for cALCL\(^{2,3}\), but the optimal treatment interval and cycles, and the necessity of maintenance therapy by using BV are unclear. Further studies are needed to
evaluate the BV treatment against cALCL. (198 words)

Key words: Brentuximab Vedotin; cutaneous ALCL

Informed Consent: was obtained from the patient

Conflict of Interest: The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References


Figure 1 Generalized erythema accompanied by desquamation before treatment of brentuximab vedotin.
Figure 2 Improvement of skin erythema accompanied by desquamation after 4 cycles of brentuximab vedotin.